Press Releases

 

Company News

  Date Title and Summary View
Aug 8, 2017
LAWRENCEVILLE, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxo...
Aug 7, 2017
OPTIMA Study at Over 60% Patient Enrollment, DMC Provides Unanimous Recommendation to Continue Celsion Summarizes Regulatory Strategy for ThermoDox® LAWRENCEVILLE, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committ...
Aug 4, 2017
Limited TASE Trading Activity Does Not Warrant Listing  Shares to Continue Listing and Trading on the NASDAQ Capital Market LAWRENCEVILLE, N.J., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it is taking steps to voluntarily delist the Company's common shares...
Aug 2, 2017
LAWRENCEVILLE, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed...
Jul 6, 2017
LAWRENCEVILLE, N.J., July 06, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direct ...
Jul 5, 2017
86% Objective Response Rate (ORR) in Phase IB Dose Escalating Study 100% ORR and 100% R0 (Margin Negative) Surgical Resection Rate at Highest Dose Cohort Increased Ratio of CD8+ Cells to Immunosuppressive T-cells Observed in 75% of Patients Indicating a Shift to a Pro-Immune Stimulatory Environment LAWRENCEVILLE, N.J., July 05, 2017 (GLOBE...
Jun 22, 2017
LAWRENCEVILLE, N.J., June 22, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has cancelled the registered direct offering of common stock announced Monday, June 19, 2017. The Company had entered into security purchase agreements with three institutional investors to purchase shares of common sto...
Jun 19, 2017
LAWRENCEVILLE, N.J., June 19, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregate of approximately $5.4 million of shares of common stock, or pre-funded warrants in lieu thereof, in a registered direc...
Jun 14, 2017
LAWRENCEVILLE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on June 13, 2017 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550...
Jun 5, 2017
100% disease control rate and 86% objective response rate reported All patients at the highest dose demonstrated an objective response rate - partial (80%) or complete (20%) response rate At the highest dose, 100% of patients achieved a R0, margin-negative, resection LAWRENCEVILLE, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporati...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Share This